Varicella zoster virus (VZV) is the causative agent of varicella (chicken pox) and herpes zoster (shingles). After primary infection, the virus remains latent in sensory ganglia, and reactivates upon weakening of the cellular immune system due to various conditions, erupting from sensory neurons and infecting the corresponding skin tissue. The current varicella vaccine (v-Oka) is highly attenuated in the skin, yet retains its neurovirulence and may reactivate and damage sensory neurons. The reactivation is sometimes associated with postherpetic neuralgia (PHN), a severe pain along the affected sensory nerves that can linger for years, even after the herpetic rash resolves. In addition to the older population that develops a secondary infection resulting in herpes zoster, childhood breakthrough herpes zoster affects a small population of vaccinated children. There is a great need for a neuro-attenuated vaccine that would prevent not only the varicella manifestation, but, more importantly, any establishment of latency, and therefore herpes zoster. The development of a genetically-defined live-attenuated VZV vaccine that prevents neuronal and latent infection, in addition to primary varicella, is imperative for eventual eradication of VZV, and, if fully understood, has vast implications for many related herpesviruses and other viruses with similar pathogenic mechanisms.
Citation: Benjamin Silver, Hua Zhu. Varicella zoster virus vaccines: potential complications and possible improvements[J]. VIROLOGICA SINICA, 2014, 29 (5): 265-273 https://doi.org/10.1007/s12250-014-3516-9
Received: 6 October, 2014; Accepted: 12 October 2014; Published: 24 October 2014
Copyright: © WIV, CAS and Springer-Verlag Berlin Heidelberg 2014
Data Availability: All relevant data are within the paper and its Supporting Information files.
Corresponding author: Hua Zhu, Phone: +1-973-972-6488, E-mail: email@example.com.
Varicella zoster virus (VZV), upon encountering a naïve host, causes a primary infection commonly known as chickenpox (varicella) (Abendroth A, et al., 1999; Arvin A M, 2001). The disease is generally considered as mild and self-resolving even in the absence of treatment (Arvin A M, 1995), although occasionally it has severe and lethal consequences (Choo P W, et al., 1995; Gilden D H, et al., 2000). The virus reaches sensory nerve ganglia where it remains latent for life, unless temporary or permanent immune suppressive conditions within the host facilitate its reactivation as shingles, or herpes zoster (HZ), affecting thoracic, cranial or lumbosacral dermatomes. The reactivation is sometimes associated with postherpetic neuralgia (PHN), a severe pain along the affected sensory nerves that can linger for years even after the herpetic rash resolves (Arvin A M, 2001; Drolet M, et al., 2010; Liesegang T J, 2004; Lydick E, et al., 1995; Opstelten W, et al., 2002). The drug treatments available to date against VZV elicited diseases are only useful in alleviating some of the symptoms and in shortening the disease duration, but cannot clear the virus or prevent establishment of latency (Hatchette T, et al., 2008; Klassen T P, et al., 2005). PHN is difficult to manage especially in the elderly, who frequently suffer from other age-related conditions and the use of the standard PHN treatment including tricyclic antidepressants, anticonvulsants and opioids can be hazardous (Drolet M, et al., 2010; Lydick E, et al., 1995).
CURRENT VZV VACCINE STATE
In 1995, the live attenuated varicella zoster virus (VZV) vaccine was approved for use in the United States (Uebe B, et al., 2002). Most children receive the first of a two-part vaccination series at their twelve-month pediatric visit. The VZV vaccine has been shown to be approximately 90% effective (Uebe B, et al., 2002). However, the initial live attenuated VZV vaccination may establish a latent infection, which can cause herpes zoster (HZ) upon reactivation (Chesnut G, et al., 2012; Uebe B, et al., 2002; Vazquez M, 2004). Herpes zoster is common, with an estimated one million new cases annually in the United States. The incidence after age 60 is 8-to-10-fold greater than in people under 60 (Harnisch J P, 1984). As the US population ages, the incidence of zoster-associated morbidity and mortality will increase. Furthermore, 40-45% of zoster patients over age 60 develop postherpetic neuralgia (PHN), pain that persists more than 4-6 weeks after acute zoster. PHN is the most common complication of zoster. Some zoster patients also develop stroke from large vessel granulomatous arteritis, multifocal infarcts from diffuse small vessel arteritis, myelitis, zoster paresis, and even pain without rash (zoster sine herpete). Zostavax, the currently available HZ vaccine, is simply a higher titer live attenuated v-Oka inoculum, which is only 51% effective in lowering the risk of HZ in the elderly, and is contraindicated during pregnancy and for those with active infections or with extremely weakened immune systems (Kimberlin D W, et al., 2007). A worrisome rise in shingles occurrence in young healthy adults in the post-vaccination era warrants doubled efforts to prevent this potentially debilitating disease (Leung J, et al., 2011; Whitley R J, 2005; Yih W K, et al., 2005).Additionally, the v-Oka vaccine is far from fully effective in preventing the initial varicella disease, as breakthrough varicella is not uncommon and occurs in 15% to 20% of vaccinated patients (Chesnut G, et al., 2012). In addition to children developing breakthrough varicella, the incidence of HZ in vaccinated children is approximately 14 cases per 100,000 person-years (Uebe B, et al., 2002). The cause of HZ in vaccinated children is controversial, but may relate to reduced immunogenicity of the varicella strain used in the vaccine (Uebe B, et al., 2002). Neurological complications of zoster are among the foremost problems, including post herpetic neuralgia, myelitis and central nervous system vasculopathy, possibly leading to stroke. One out of three people in the USA will develop shingles and there are an estimated one million new cases each year. Therefore, it is essential to understand how VZV establishes and reactivates from latency in ganglia, and how the host immune system controls primary, latent and reactivated VZV infection. A better understanding of VZV pathogenesis and neuroinvasion will lay the groundwork for a neuro-attenuated vaccine that will circumvent all disease caused by VZV in the yet-to-be vaccinated, or exposed, populations.
RESEARCH OBSTACLES AND STATE OF THE ART TECHONOLGY
VZV is fundamentally different from the simplex viruses and unique in the herpes paradigm. For instance, VZV has a strict cellular association in cultured cells and is almost entirely human host restricted. These qualities posed many challenges in the efforts to characterize its genes and set it apart from the other alphaherpesviruses, whose host promiscuity and capacity to generate sufficient amounts of cell-free particles allowed for a much earlier understanding of their replication and pathogenesis. Previous methods of creating recombinant VZV deletion mutants utilized the four-cosmid system, in which VZV DNA was split into four overlapping segments called cosmids. In this system, one cosmid would be made to contain the desired mutation, and all four segments are then co-transfected into human cells to produce the recombinant VZV variant upon multiple homologous recombination events (Cohen J I, et al., 1993; Niizuma T, et al., 2003). This method, however, was inefficient as it required co-transfection of four large cosmids into human cells and multiple successful homologous recombination events within a single cell to create the fulllength viral genome (Nagaike K, et al., 2004). Fortunately, building upon the overlapping cosmid system, the bacterial artificial chromosome (BAC) technology yielded a new and more efficient method for generating recombinant viral mutants. BACs are very useful due to their low copy number and the ease of producing mutants with the advantage of harboring them in modified E. coli with λ prophage homologous recombination machinery. Insertion of a BAC vector into one of the genomic cosmids via homologous recombination is the key step that allows for the rapid creation of recombinant viruses that can be genetically manipulated in E. coli. In order to circumvent some of the problems in the study of VZV with cosmids, four cosmids (pvFsp73, pvSpe14, pvPme19, and pvSpe23) with overlapping genomic sequences of VZV were created (Figure 1A). The BAC vector (pUSF-6) containing the origin of bacteria replication and selectable markers is inserted in between VZV ORF60 and 61 in the pvSpe23 cosmid (Figure 1B) (Warden C, et al., 2011). The overlaps between cosmids allow for homologous recombination between the segments and formation of a single, circular DNA sequence that encompasses a full-length infectious VZV genome. Viral replication and plaque formation can be visualized due to the GFP marker in the BAC vector.
However, it is near impossible to quantify the amount of GFP expressed to accurately analyze the growth kinetics of viruses, especially when an animal model is used. For this reason, bioluminescent imaging (BLI) has become a powerful tool for studying herpesviruses in vivo and in vitro (Contag C H, et al., 1997; Rehemtulla A, et al., 2000). BLI is a novel method that enables the monitoring and measurement of viral replication in live cells, tissues and animals. The method involves the use of reporter genes, such as luciferase, that are inserted into the viral genome and expressed only as viral proteins are expressed during replication (Hastings J W, 1983; Kurfurst M, et al., 1983). When exposed to the D-luciferin substrate, luciferase will catalyze the substrate’s bioluminescent oxidation, thus producing light whose intensity is dependent on the amount of luciferase present (Doyle T C, et al., 2004; Hastings J W, 1983). BLI has several advantages over other imaging systems such as fluorescent-based imaging. Firstly, BLI is especially effective for in vivo applications because D-luciferin can rapidly permeate the tissues of a living animal, allowing the substrate to reach any site of infection in the body, and therefore poses no limits for in vivo applications.
Additionally, in comparison to GFP, the shorter wavelength of the photons emitted from the luciferaseluciferin reaction allows the light to penetrate tissues and return to the detection instrument for accurate quantification. D-luciferin also has a low toxicity that allows the substrate to be used repeatedly in the same animal (Contag C H, et al., 1997; Rehemtulla A, et al., 2000). Above all else, the main advantage of BLI over other methods is that it can monitor viral growth and provide real-time detection of spatial and temporal growth of viruses in vivo. This makes quantification of viral growth in vivo possible, an attribute necessary for analyzing recombinant viral growth kinetics and tissue tropism (Collaco A M, et al., 2005; Contag C H, et al., 2002; Fan S, et al., 2005; White M R, et al., 1995). Coupling VZV BAC technology with BLI by adding a luciferase gene into viral DNA offers even more advantages for understanding VZV pathogenesis. A luciferase-expressing virus can be used to detect areas of viral infection and, more importantly, study the growth kinetics of recombinant mutated viruses and interpret the resulting data to identify tissue-tropic genes. Furthermore, using a bioluminescent-capable VZV facilitates studies of anti-VZV compounds, VZV pathogenesis and mutational analyses. The first step to generate a replication competent VZV with a luciferase marker (VZVLUC) is to insert a firefly luciferase expression cassette into the intergenic space between ORF65 and ORF66 (Figure 1C) (Zhang Z, et al., 2007). This DNA is then transfected into ARPE-19 cells (a human retinal pigment epithelial cell line) to create the VZVLUC virus. Bioluminescence is only detected in VZVLUC-infected cells (Figure 1D).
VZV MUTATIONAL ANALYSES AND ORF7
Functional analysis of each ORF can be performed by mutational analysis of deletion mutants. PCR methods are employed to replace each ORF with a selectable marker via homologous recombination in bacteria and the resulting BAC clone can be transfected into human cells for virus propagation and mutational analysis. Despite having the smallest genome of the eight herpesviruses, not even half of VZV’s ORFs have been characterized previously (Zhang Z, et al., 2007). Creating deletion mutants using the aforementioned methods has allowed for functional studies of VZV’s 70 unique ORFs. Understanding the roles and essentiality of each ORF is the first step to identify VZV tissue tropic factors, which will contribute to the development of a skin- and neuroattenuated vaccine.
The method for generating VZV mutation clones and the corresponding rescue viruses is the galK-based mutagenesis selection/counterselection system. The galK-based mutagenesis also relies on the homologous recombination system mentioned above, but this system possesses an advantage over an antibiotic selection system in that no foreign DNA will remain in the rescue virus. The E. coli SW102 strain is used because the galK gene of the galactose operon in these bacteria is defective. As a result, the strain cannot survive in a medium where galactose is the only source of carbon. This system supplies the galK gene in trans (within the BAC) so that the bacteria will only grow when a homologous recombination event replaces ORFX with galK (Warming S, et al., 2005; Zhang Y, et al., 2000; Zhang Z, et al., 2008).
Using the aforementioned methods, a library of all 70 ORF deletion mutants was created and screened in melanoma cells and skin organ cultures (Zhang Z, et al., 2010), in an effort to reveal all the genes involved in skin tropism. In addition to previously known tissue tropic genes, we found ORF7 to be the single novel gene whose absence prevented VZV replication and spread in skin organ culture ex vivo and in an in vivo SCID-hu mouse model. A schematic of the process for making the ORF7S (where 3 stop codons have been inserted into the ORF7 gene), is outlined in Figure 2.
The essentiality of each ORF is determined by transfecting ARPE-19 cells with mutant DNA and observing viral replication and plaque growth. Through the systematic deletion of each ORF and the transfection of mutants into ARPE-19 cells, the essentiality of each ORF can be determined. If the ORF is nonessential, a viral plaque will be observable within 3–5 days postinfection. A viral plaque that is much smaller than that of a WT infection suggests that the respective ORF strongly influences growth. If no plaque formation is observed, the ORF is likely to be essential for viral replication. A color-coded map of the VZV genome is presented in Figure 3 to represent the results of the global scale mutational analysis of the individual ORF essentiality for viral replication.
Subsequent to the identification of a novel skintropic factor, we sought to identify any potential neurotropic factor of VZV by screening the deletion mutants deemed dispensable for viral replication in culture. These genes were targeted due to their capacity to grow without significant defect in culture, with a strong likelihood that one of the genes would be responsible for or involved in tissue tropism, as was seen for the skintropic screening. It was hypothesized that any identified genes that prevent growth or spread in neural models, while remaining replication competent in epithelial or fibroblast cells, would therefore be potential candidates for a live-attenuated vaccine against latency establishment and herpes zoster.18 ORF deletion mutants were transfected, re-spectively, into differentiated neuroblastoma (SHSY5Y) cells and hESC-derived neurons. 17 ORF deletion mutants grew normally in these neuronal models, while only ORF7 deletion mutant proved to be a neurotropic factor, in that the virus failed to replicate and spread in both SH-SY5Y and hESC-derived neurons. In addition, ORF7 deletion mutant VZV was screened ex vivo and in vivo in fetal dorsal root ganglion models (SCID-DRG). The SCID-hu DRG model has proven an excellent tool for the study of VZV pathogenesis and latency in human neurons. Moreover, factors implicated in neuropathogenesis are being brought to light by employing this model. Zerboni et al. have also demonstrated that the live attenuated VZV vaccine strain has similar replication properties to the clinical VZV isolates, which correlates with our results in differentiated neuroblastoma cells (Zerboni L, et al., 2011; Zerboni L, et al., 2010). Our work led to the characterization of ORF7 as the first, and currently only, known neurotropic factor of VZV. Of special interest is the fact that an ORF7 deletion mutant virus can prevent viral spread in skin and in neurons, the two tissues of VZV disease manifestation. Figure 4 presents VZV growth curves for ex vivo SOC (A) and in vivo SCIDhu DRG (B) to demonstrate the different models for studying VZV and the tissue tropism of ORF7.
ORF7 OF VZV CHARACTERIZED
ORF7 protein is a virion component of unknown function that localizes to the Golgi compartment within infected cells, suggesting a possible role in efficient viral packaging and egress. ORF7 appears to have a determining function in cell-to-cell fusion and it is likely to work in conjunction with other viral or cellular proteins to achieve this effect. Another possibility might be that ORF7 is important in the process of viral entry into cells, specifically in fusing the viral envelope with the cell membrane. However, it has been speculated that VZV does not favor this mechanism as a mode of entry, particularly in epithelial cells, which explains its almost exclusive cell-association in tissue culture (Gershon M D, et al., 2010). VZV, unlike all other alphaherpesviruses, is confined to the cell body instead of being released into the culture medium by cell lysis, which is an indication that VZV has evolved alternative modes of spread, favoring cell-to-cell rather than virusto-cell spread. It was suggested by Gershon et al. that the cation-independent mannose-6-phosphate receptor (MPRci) present on most VZV permissive cells may confine VZV to a cell associated status by re-routing nascent virions to the late endosome. This pathway is averted in suprabasal epidermis keratinocytes, which lose their MPRci receptors as they mature, thus allowing cell free particle release (Gershon M D, et al., 2010). It is not inconceivable that the cell-associated spread within the host could be a means to evade the immune system during natural infection in order to maintain latency (Cole N L, et al., 2003), in contrast with the cell-free mode of transmission from host to host.
Syncytia formation may be critical for neuroinvasion, thus a polykaryon-defective VZV mutant, such as ORF7D, would be unable to efficiently establish infection of neural tissue. It has been suggested that, within human DRG, VZV infects neurons via fusion of infected satellite cells with the neuronal soma, forming neuronsatellite cell complexes (Reichelt M, et al., 2008; Zerboni L, et al., 2010). Since viral spread within nervous tissue is dramatically impaired, absence of ORF7 protein may trigger loss of infectivity specifically due to the incapacity of the virus to fuse potentially infected satellite cells with sensory neurons; however, further evidence is needed to validate this mechanism. An alternative possibility is that although in epithelial cells ORF7 works to sort virions to the Golgi after the first envelopment event, the situation is different in neurons. Here, secondary envelopment may occur at a different site, as is the case with HSV-1, which acquires its secondary envelope from varicosities and growth cones at the tip of the axons or at axonal mid-distal regions (Saksena M M, et al., 2006). In this case, ORF7 may be essential for sorting to this secondary envelopment site, which remains to be determined.
These findings could open multiple avenues for future investigations into the mechanism of VZV neuroinvasion, which will have an important impact upon VZV prevention and therapy. ORF7D VZV, unlike the commonly used vaccine strain v-Oka, is a pure and genetically defined strain lacking ability to infect both human skin and nervous tissue in vivo, thus meeting crucial safety and genetic stability criteria for a next generation chickenpox and shingles neuro-attenuated vaccine. ORF7D could also be used as a safer viral vector for gene therapy and for immunization against other viral or even bacterial antigens. Complete prevention of both varicella and herpes zoster is the only path that will lead to eradication of VZV, and a neuroattenuated, or an otherwise highly immunogenic, VZV vaccine is required.
COMPLIANCE WITH ETHICS GUIDELINES
All the authors declare that they have no competing interests. This article does not contain any studies with human or animals subjects performed by any of the authors.
- . Abendroth A, Arvin A. 1999. Varicella-zoster virus immune evasion. Immunological reviews, 168: 143-156.
- . Arvin A M. 1995. Aspects of the host response to varicella-zoster virus: a review of recent observations. Neurology, 45: S36-37.
- . Arvin A M. 2001. Varicella-zoster virus: molecular virology and virus-host interactions. Curr Opin Microbiol, 4: 442-449.
- . Chesnut G, McClain D, Galeckas K. 2012. Varicella-zoster virus in children immunized with the varicella vaccine. Cutis, 90: 114-116.
- . Choo P W, Donahue J G, Manson J E, Platt R. 1995. The epide-miology of varicella and its complications. J Infect Dis, 172: 706-712.
- . Cohen J I, Seidel K E. 1993. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc Natl Acad Sci U S A, 90: 7376-7380.
- . Cole N L, Grose C. 2003. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev Med Virol, 13: 207-222.
- . Collaco A M, Rahman S, Dougherty E J, Williams B B, Geusz M E. 2005. Circadian regulation of a viral gene promoter in live transgenic mice expressing firefly luciferase. Mol Imaging Biol, 7: 342-350.
- . Contag C H, Bachmann M H. 2002. Advances in in vivo biolumin-escence imaging of gene expression. Annu Rev Biomed Eng, 4: 235-260.
- . Contag C H, Spilman S D, Contag P R, Oshiro M, Eames B, Dennery P, Stevenson D K, Benaron D A. 1997. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol, 66: 523-531.
- . Doyle T C, Burns S M, Contag C H. 2004. In vivo biolumine-scence imaging for integrated studies of infection. Cell Micro-biol, 6: 303-317.
- . Drolet M, Brisson M, Schmader K E, Levin M J, Johnson R, Oxman M N, Patrick D, Blanchette C, Mansi J A. 2010. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 182: 1731-1736.
- . Dulal K, Zhang Z, Zhu H. 2009. Development of a gene cap-ture method to rescue a large deletion mutant of human cytomegalovirus. Journal of Virological Methods, 157: 180-187.
- . Dulal K, Silver B, Zhu H. 2012. Use of Recombination-Mediated Genetic Engineering for Construction of Rescue Human Cytomegalovirus Bacterial Artificial Chromosome Clones. Biomed and Biotechnol.
- . Fan S, Maguire C A, Ramirez S H, Bradel-Tretheway B, Sapinoro R, Sui Z, Chakraborty-Sett S, Dewhurst S. 2005. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods, 125: 23-33.
- . Gershon M D, Gershon A A. 2010. VZV infection of keratinocytes: production of cell-free infectious virions in vivo. Curr Top Microbiol Immunol, 342: 173-188.
- . Gilden D H, Kleinschmidt-DeMasters B K, LaGuardia J J, Maha-lingam R, Cohrs R J. 2000. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med, 342: 635-645.
- . Harnisch J P. 1984. Zoster in the elderly: clinical, immunologic and therapeutic considerations. J Am Geriatr Soc, 32: 789-793.
- . Hastings J W. 1983. Biological diversity, chemical mechanisms, and the evolutionary origins of bioluminescent systems. J Mol Evol, 19: 309-321.
- . Hatchette T, Tipples G A, Peters G, Alsuwaidi A, Zhou J, Mailman T L. 2008. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J, 27: 75-77.
- . Kimberlin D W, Whitley R J. 2007. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med, 356: 1338-1343.
- . Klassen T P, Hartling L, Wiebe N, Belseck E M. 2005. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev: CD002980.
- . Kurfurst M, Ghisla S, Hastings J W. 1983. Bioluminescence emission from the reaction of luciferase-flavin mononucleotide radical with O2. Biochemistry, 22: 1521-1525.
- . Leung J, Harpaz R, Molinari N A, Jumaan A, Zhou F. 2011. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis, 52: 332-340.
- . Liesegang T J. 2004. Herpes zoster virus infection. Curr Opin Ophthalmol, 15: 531-536.
- . Lydick E, Epstein R S, Himmelberger D, White C J. 1995. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology, 45: S52-53.
- . Nagaike K, Mori Y, Gomi Y, Yoshii H, Takahashi M, Wagner M, Koszinowski U, Yamanishi K. 2004. Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chro-mosome in Escherichia coli. Vaccine, 22: 4069-4074.
- . Niizuma T, Zerboni L, Sommer M H, Ito H, Hinchliffe S, Arvin A M. 2003. Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J Virol, 77: 6062-6065.
- . Opstelten W, Mauritz J W, de Wit N J, van Wijck A J, Stalman W A, van Essen G A. 2002. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract, 19: 471-475.
- . Rehemtulla A, Stegman L D, Cardozo S J, Gupta S, Hall D E, Contag C H, Ross B D. 2000. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia, 2: 491-495.
- . Reichelt M, Zerboni L, Arvin A M. 2008. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol, 82: 3971-3983.
- . Saksena M M, Wakisaka H, Tijono B, Boadle R A, Rixon F, Takahashi H, Cunningham A L. 2006. Herpes simplex virus type 1 accumulation, envelopment, and exit in growth cones and varicosities in mid-distal regions of axons. J Virol, 80: 3592-3606.
- . Uebe B, Sauerbrei A, Burdach S, Horneff G. 2002. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr, 161: 442-444.
- . Vazquez M. 2004. Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine. Curr Opin Pediatr, 16: 80-84.
- . Warden C, Tang Q, Zhu H. 2011. Herpesvirus BACs: past, present, and future. J Biomed Biotechnol: 124595.
- . Warming S, Costantino N, Court D L, Jenkins N A, Copeland N G. 2005. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res, 33: e36.
- . White M R, Masuko M, Amet L, Elliott G, Braddock M, Kingsman A J, Kingsman S M. 1995. Real-time analysis of the transcriptional regulation of HIV and hCMV promoters in single mammalian cells. J Cell Sci, 108(Pt 2): 441-445.
- . Whitley R J. 2005. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis, 191: 1999-2001.
- . Yih W K, Brooks D R, Lett S M, Jumaan A O, Zhang Z, Clements K M, Seward J F. 2005. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health, 5: 68.
- . Zerboni L, Arvin A. 2011. Investigation of varicella-zoster virus neurotropism and neurovirulence using SCID mouse-human DRG xenografts. J Neurovirol, 17: 570-577.
- . Zerboni L, Reichelt M, Arvin A. 2010. Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts. Curr Top Microbiol Immunol, 342: 255-276.
- . Zhang Y, Muyrers J P, Testa G, Stewart A F. 2000. DNA cloning by homologous recombination in Escherichia coli. Nat Biotechnol, 18: 1314-1317.
- . Zhang Z, Huang Y, Zhu H. 2008. A highly efficient protocol of generating and analyzing VZV ORF deletion mutants based on a newly developed luciferase VZV BAC system. J Virol Methods, 148: 197-204.
- . Zhang Z, Rowe J, Wang W, Sommer M, Arvin A, Moffat J, Zhu H. 2007. Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. J Virol, 81: 9024-9033.
- . Zhang Z, Selariu A, Warden C, Huang G, Huang Y, Zaccheus O, Cheng T, Xia N, Zhu H. 2010. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS pathogens, 6: e1000971.